Search

Your search keyword '"Powles, Thomas"' showing total 107 results
Start Over Author "Powles, Thomas" Publisher american society of clinical oncology
107 results on '"Powles, Thomas"'

2. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.

Author

Motzer, Robert J., Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E., Alekseev, Boris, Rha, Sun Young, Merchan, Jaime, Goh, Jeffrey C., Lalani, Aly-Khan A., De Giorgi, Ugo, Melichar, Bohuslav, Hong, Sung-Hoo, Gurney, Howard, Méndez-Vidal, María José, Kopyltsov, Evgeny, Tjulandin, Sergei, Gordoa, Teresa Alonso, and Kozlov, Vadim

Published
2024
Full Text
View/download PDF

4. Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study.

Author

Van Der Heijden, Michiel Simon, Powles, Thomas, Gupta, Shilpa, Bedke, Jens, Kikuchi, Eiji, De Wit, Ronald, Galsky, Matt D., Duran, Ignacio, Necchi, Andrea, Retz, Margitta, Yu, Evan Y., Hoffman-Censits, Jean H., Iyer, Gopa, Park, Se Hoon, Su, Wen-Pin, Parmar, Hema, Guan, Xuesong, Gorla, Seema Rao, Homet Moreno, Blanca, and Valderrama, Begoña Pérez

Published
2024
Full Text
View/download PDF

5. Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).

Author

Choueiri, Toni K., Tomczak, Piotr, Park, Se Hoon, Venugopal, Balaji, Ferguson, Thomas, Symeonides, Stefan N., Hajek, Jaroslav, Chang, Yen-Hwa, Lee, Jae-Lyun, Sarwar, Naveed, Gurney, Howard, Gross-Goupil, Marine, Mahave, Mauricio, Haas, Naomi B., Sawrycki, Piotr, Zhang, Tian, Cornell, Jerry, Elfiky, Aymen, Burgents, Joseph E., and Powles, Thomas

Published
2024
Full Text
View/download PDF

11. Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study.

Author

Saliby, Renee Maria, Xie, Wanling, Wells, J Connor, Saad, Eddy, Eid, Marc, Labaki, Chris, Semaan, Karl, Ferrier, Evan, Lemelin, Audreylie, Suárez, Cristina, Ruiz-Morales, Jose Manuel, Powles, Thomas, Wood, Lori, Ebrahimi, Hedyeh, de Velasco, Guillermo, Takemura, Kosuke null, Agarwal, Neeraj, Braun, David A., Heng, Daniel Yick Chin, and Choueiri, Toni K.

Published
2024
Full Text
View/download PDF

12. Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).

Author

Wells, Connor, Ferrier, Evan, Lemelin, Audreylie, Powles, Thomas, Pal, Sumanta Kumar, Ebrahimi, Hedyeh, Agarwal, Neeraj, Beuselinck, Benoit, Bjarnason, Georg A., Wood, Lori, Canil, Christina M., Saliby, Renee Maria, de Velasco, Guillermo, McKay, Rana R., Tran, Ben, Suárez, Cristina, Templeton, Arnoud J., Choueiri, Toni K., and Heng, Daniel Yick Chin

Published
2024
Full Text
View/download PDF

13. Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis.

Author

Gupta, Mehul, Wells, Connor, Regan, Meredith M., Xie, Wanling, Navani, Vishal, Saliby, Renee Maria, Basappa, Naveen S., Donskov, Frede, Yuasa, Takeshi, Takemura, Kosuke null, Kollmannsberger, Christian K., Crumbaker, Megan, Lalani, Aly-Khan A., Powles, Thomas, Pal, Sumanta Kumar, McKay, Rana R., Lee, Jae-Lyun, Kanesvaran, Ravindran, Choueiri, Toni K., and Heng, Daniel Yick Chin

Published
2024
Full Text
View/download PDF

15. Development of a patient-centered health-related quality of life (HRQOL) measure for metastatic renal cell carcinoma (mRCC): A three-phase study.

Author

Bergerot, Cristiane Decat, Castro, Daniela V., Bergerot, Paulo Gustavo, Mercier, Benjamin D., Nally, Elizabeth, Ali, Adil A., Philip, Errol James, Buso, Murilo, Hutson, Thomas E., Grünwald, Viktor, Bex, Axel, Psutka, Sarah P., Rini, Brian I., Plimack, Elizabeth R., Master, Viraj A., Albiges, Laurence, Choueiri, Toni K., Pal, Sumanta Kumar, and Powles, Thomas

Published
2024
Full Text
View/download PDF

16. Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.

Author

Tannir, Nizar M., Escudier, Bernard, McDermott, David F., Burotto, Mauricio, Choueiri, Toni K., Hammers, Hans J., Plimack, Elizabeth R., Porta, Camillo, George, Saby, Powles, Thomas, Donskov, Frede, Atkins, Michael B., Kollmannsberger, Christian K., Grimm, Marc-Oliver, Tomita, Yoshihiko, Rini, Brian I., Jiang, Ruiyun, Desilva, Heshani, Lee, Chung-Wei, and Motzer, Robert J.

Published
2024
Full Text
View/download PDF

17. Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial.

Author

Bourlon, Maria Teresa, Escudier, Bernard, Burotto, Mauricio, Powles, Thomas, Apolo, Andrea B., Shah, Amishi Yogesh, Porta, Camillo, Suárez, Cristina, Barrios, Carlos H., Richardet, Martin, Gurney, Howard, Kessler, Elizabeth R., Tomita, Yoshihiko, Bedke, Jens, Wang, Fong, Wang, Peter, Panzica, Julie, Fedorov, Viktor, Motzer, Robert J., and Choueiri, Toni K.

Published
2024
Full Text
View/download PDF

18. Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.

Author

Powles, Thomas, Albiges, Laurence, Jalkanen, Katriina Johanna, De Velasco, Guillermo, Burotto, Mauricio, Ghatalia, Pooja, Suárez, Cristina, Lam, Elaine T., Iacovelli, Roberto, Gumus, Mahmut, Verzoni, Elena, Kollmannsberger, Christian K., Stadler, Walter Michael, Venugopal, Balaji, Shinde, Reshma, Saretsky, Todd L., He, Li, Vickery, Donna, Choueiri, Toni K., and Rini, Brian I.

Published
2024
Full Text
View/download PDF

20. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.

Author

Kamat, Ashish M., Apolo, Andrea B., Babjuk, Marek, Bivalacqua, Trinity J., Black, Peter C., Buckley, Roger, Campbell, Matthew T., Compérat, Eva, Efstathiou, Jason A., Grivas, Petros, Gupta, Shilpa, Kurtz, Neil J., Lamm, Donald, Lerner, Seth P., Li, Roger, McConkey, David J., Palou Redorta, Joan, Powles, Thomas, Psutka, Sarah P., and Shore, Neal

Published
2023
Full Text
View/download PDF

22. Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).

Author

Suárez, Cristina, Larkin, James M.G., Patel, Poulam, Valderrama, Begoña P., Rodriguez-Vida, Alejo, Glen, Hilary, Thistlethwaite, Fiona, Ralph, Christy, Srinivasan, Gopalakrishnan, Mendez-Vidal, Maria Jose, Hartmaier, Ryan, Markovets, Aleksandra, Prendergast, Aaron, Szabados, Bernadett, Mousa, Kelly, and Powles, Thomas

Published
2023
Full Text
View/download PDF

23. A randomized, double-blind, biomarker-selected, phase ii clinical trial of maintenance poly adp-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma

Author

Crabb, Simon J., Hussain, Syed, Soulis, Eileen, Hinsley, Samantha, Dempsey, Laura, Trevethan, Avril, Song, YeePe, Barber, Jim, Frew, John, Gale, Joanna, Faust, Guy, Brock, Susannah, McGovern, Ursula, Parikh, Omi, Enting, Deborah, Sundar, Santhanam, Ratnayake, Gihan, Lees, Kathryn, Birtle, Alison J., Powles, Thomas, and Jones, Robert J.

Abstract

PURPOSE:\ud A DNA repair deficiency (DRD) phenotype exists within a subset of metastatic urothelial carcinomas (mUC) predicting benefit from platinum-based chemotherapy. We tested switch maintenance therapy with the poly ADP-ribose polymerase inhibitor rucaparib, following chemotherapy, for DRD biomarker–positive mUC.\ud \ud METHODS:\ud DRD biomarker–positive mUC patients, within 10 weeks of chemotherapy, and without cancer progression, were randomly assigned (1:1) to maintenance rucaparib 600 mg twice a day orally, or placebo, until disease progression. The primary end point was progression-free survival (PFS). Statistical analysis targeted a hazard ratio of 0.5 with a 20% one-sided α for this signal-seeking trial. PFS (RECIST 1.1) was compared between trial arms, by intention to treat, within a Cox model.\ud \ud RESULTS:\ud Out of 248 patients, 74 (29.8%) were DRD biomarker–positive and 40 were randomly assigned. A total of 12 (60%) and 20 (100%) PFS events occurred in the rucaparib and placebo arms, respectively (median follow-up was 94.6 weeks in those still alive). Median PFS was 35.3 weeks (80% CI, 11.7 to 35.6) with rucaparib and 15.1 weeks (80% CI, 11.9 to 22.6) with placebo (hazard ratio, 0.53; 80% CI, 0.30 to 0.92; one-sided P = .07). In the safety population (n = 39) treatment-related adverse events were mostly low grade. Patients received a median duration of 10 rucaparib or six placebo cycles on treatment. Treatment-related adverse events (all grades) of fatigue (63.2% v 30.0%), nausea (36.8% v 5.0%), rash (21.1% v 0%), and raised alanine aminotransferase (57.9% v 10%) were more common with rucaparib.\ud \ud CONCLUSION:\ud Maintenance rucaparib, following platinum-based chemotherapy, extended PFS in DRD biomarker-selected patients with mUC and was tolerable. Further investigation of poly ADP-ribose polymerase inhibition in selected patients with mUC is warranted.

Published
2022

24. A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.

Author

Crabb, Simon J., Hussain, Syed, Soulis, Eileen, Hinsley, Samantha, Dempsey, Laura, Trevethan, Avril, Song, YeePei, Barber, Jim, Frew, John, Gale, Joanna, Faust, Guy, Brock, Susannah, McGovern, Ursula, Parikh, Omi, Enting, Deborah, Sundar, Santhanam, Ratnayake, Gihan, Lees, Kathryn, Birtle, Alison J., and Powles, Thomas

Published
2023
Full Text
View/download PDF

25. Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.

Author

Kasi, Pashtoon M., Fehringer, Gordon, Taniguchi, Hiroya, Starling, Naureen, Nakamura, Yoshiaki, Kotani, Daisuke, Powles, Thomas, Li, Bob T., Pusztai, Lajos, Aushev, Vasily N., Kalashnikova, Ekaterina, Sharma, Shruti, Malhotra, Meenakshi, Demko, Zachary P., Aleshin, Alexey, Rodriguez, Angel, Billings, Paul R., Grothey, Axel, Taieb, Julien, and Cunningham, David

Subjects
EXPERIMENTAL design, BIOMARKERS, CIRCULATING tumor DNA, EARLY detection of cancer, STATISTICAL power analysis, CANCER relapse
Abstract

PURPOSE: Earlier detection of cancer recurrence using circulating tumor DNA (ctDNA) to detect molecular residual disease (MRD) has the potential to dramatically affect cancer management. We review evidence supporting the use of ctDNA as a biomarker for detection of MRD and highlight the potential impact that ctDNA testing could have on the conduct of clinical trials. METHODS: We searched the literature using MEDLINE (via PubMed) for articles from January 1, 2000, focusing on studies that assessed ctDNA as a predictor of cancer recurrence. Broadly focused searches on ctDNA and cancer were also performed to provide additional background information. www.clinialtrials.gov was searched to identify trials that incorporate ctDNA testing. RESULTS: Numerous studies across different cancer types indicate that ctDNA-based MRD detection predicts recurrence with high sensitivity and specificity, and with lead times that precede standard imaging by up to 12 months. Recently, ctDNA testing has started being used to enroll MRD-positive patients at high risk of recurrence into trials, promising gains in statistical power that allow clinical utility to be demonstrated with smaller cohorts. Trials where ctDNA testing based-MRD detection is used to stratify patients into low or high-risk categories for treatment assignment are also ongoing. In addition, there is increasing evidence supporting the use of ctDNA dynamics or clearance as a surrogate end point, which could significantly reduce trial duration. CONCLUSION: ctDNA-based trial enrichment across many cancers seems likely to become increasingly common for cost- and time-reduction benefits. Trial efficiency could also benefit from using ctDNA as a surrogate end point, leading to accelerated approval of new therapeutics. A clear demonstration of efficacy from trials that use ctDNA-based MRD detection to assign treatment could transform clinical practice. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer.

Author

Vuky, Jacqueline, Balar, Arjun V., Castellano, Daniel, O'Donnell, Peter H., Grivas, Petros, Bellmunt, Joaquim, Powles, Thomas, Bajorin, Dean, Hahn, Noah M., Savage, Mary J., Fang, Xiao, Godwin, James Luke, Frenkl, Tara L., Homet Moreno, Blanca, de Wit, Ronald, and Plimack, Elizabeth R.

Published
2020
Full Text
View/download PDF

28. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.

Author

Rini, Brian I., Plimack, Elizabeth R., Stus, Viktor, Gafanov, Rustem, Waddell, Tom, Nosov, Dmitry, Pouliot, Frederic, Alekseev, Boris, Soulieres, Denis, Melichar, Bohuslav, Vynnychenko, Ihor O., Azevedo, Sergio Jobim, Borchiellini, Delphine, McDermott, Raymond S., Bedke, Jens, Tamada, Satoshi, Wu, Sterling, Burgents, Joseph, Molife, L. Rhoda, and Powles, Thomas

Published
2023
Full Text
View/download PDF

29. Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized,...

Author

Choueiri, Toni K., Albiges, Laurence, Tomczak, Piotr, Suárez, Cristina, Voss, Martin H., de Velasco, Guillermo, Chahoud, Jad, Procopio, Giuseppe, Mahammedi, Hakim, Zengerling, Friedemann, Kim, Chan, Gupta, Suyasha, Bergthold, Guillaume, Liu, Bo, Kalaitzidou, Melania, Huseni, Mahrukh A., Scheffold, Christian, Powles, Thomas, and Pal, Sumanta Kumar

Published
2023
Full Text
View/download PDF

32. A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104).

Author

Kamat, Ashish M., Lotan, Yair, Roupret, Morgan, Steinberg, Gary D., Inman, Brant A., Powles, Thomas, Redorta, J. Palou, Porten, Sima P., Kulkarni, Girish S., Uchio, Edward M., Gorla, Seema Rao, Haas, Gabriel P., Yu, Yao, Chia, Yen Lin, Birrenkott, Matthew, and Kates, Max R.

Published
2023
Full Text
View/download PDF

33. Final results from SAUL, a single-arm international real-world study of atezolizumab (atezo) in 1004 patients (pts) with pretreated locally advanced/metastatic urinary tract carcinoma (UTC).

Author

Sternberg, Cora N., Loriot, Yohann, Choy, Ernest, Castellano, Daniel, Lopez-Rios Moreno, Fernando, Banna, Giuseppe Luigi, De Giorgi, Ugo, Masini, Cristina, Bamias, Aristotelis, Garcia del Muro, Xavier, Duran, Ignacio, Powles, Thomas, Gamulin, Marija, Zengerling, Friedemann, Geczi, Lajos, Gedye, Craig, Huddart, Robert A, Kandula, Geetha, Skamnioti, Pari, and Merseburger, Axel S.

Published
2023
Full Text
View/download PDF

34. Impact of smoking status (SS) on the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first line (1L) immuno-oncology (IO)-combination regimens: Results from the International Metastatic Renal Cell Carcinoma...

Author

Gebrael, Georges, Saad, Eddy, Labaki, Chris, Saliby, Renee Maria, Sayegh, Nicolas, Wells, J Connor, Semaan, Karl, Eid, Marc, Takemura, Kosuke, Ernst, Matthew Scott, Lemelin, Audreylie, Basappa, Naveen S., Wood, Lori, Powles, Thomas, Ernst, D. Scott, Kapoor, Anil, Xie, Wanling, Agarwal, Neeraj, Heng, Daniel Yick Chin, and Choueiri, Toni K.

Published
2023
Full Text
View/download PDF

35. Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.

Author

Albiges, Laurence, Beckermann, Katy, Miller, Wilson H., Goh, Jeffrey C., Gajate, Pablo, Harris, Carole A., Suárez, Cristina, Peer, Avivit, Park, Se Hoon, Stadler, Walter Michael, Weickhardt, Andrew James, Faust, Guy, Fong, Peter C.C., Waddell, Tom, Venugopal, Balaji, Yin, Lina, Wang, Ding, Perini, Rodolfo F., and Powles, Thomas

Published
2023
Full Text
View/download PDF

36. Health-related quality of life (HR-QOL) measures in renal cell carcinoma (RCC): Patient-reported relevance of items of the FKSI-19, EORTC QLQ-C30, and EQ-5D.

Author

Bergerot, Cristiane Decat, Mercier, Benjamin D, Castro, Daniela V., Bergerot, Paulo Gustavo, Toms, Charlotte, Ali, Adil A, Philip, Errol James, Lages, Dr. Paulo Sergio, Mota, Augusto C. A., Hutson, Thomas E., Grünwald, Viktor, Bex, Axel, Psutka, Sarah P., Rini, Brian I., Plimack, Elizabeth R., Master, Viraj A., Albiges, Laurence, Choueiri, Toni K., Pal, Sumanta Kumar, and Powles, Thomas

Published
2023
Full Text
View/download PDF

37. Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo+Ipi): Results from the International mRCC Database Consortium (IMDC).

Author

Lemelin, Audreylie, Takemura, Kosuke, Ernst, Matthew Scott, Wells, J Connor, Donskov, Frede, Porta, Camillo, de Velasco, Guillermo, Davis, Ian D., Wood, Lori, Pal, Sumanta Kumar, Hansen, Aaron Richard, Kollmannsberger, Christian K., Bjarnason, Georg A., Tran, Ben, Li, Haoran, Kanesvaran, Ravindran, Powles, Thomas, McKay, Rana R., Choueiri, Toni K., and Heng, Daniel Yick Chin

Published
2023
Full Text
View/download PDF

41. Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).

Author

Motzer, Robert J., Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E., Alekseev, Boris, Rha, Sun Young, Merchan, Jaime R., Goh, Jeffrey C., Kapoor, Anil, De Giorgi, Ugo, Melichar, Bohuslav, Hong, Sung-Hoo, Gurney, Howard, Rodriguez-Lopez, Karla, He, Cixin S., Okpara, Chinyere, McKenzie, Jodi, and Choueiri, Toni K.

Published
2023
Full Text
View/download PDF

43. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.

Author

Cella, David, Escudier, Bernard, Tannir, Nizar M., Powles, Thomas, Donskov, Frede, Peltola, Katriina, Schmidinger, Manuela, Heng, Daniel Y.C., Mainwaring, Paul N., Hammers, Hans J., Lee, Jae Lyun, Roth, Bruce J., Marteau, Florence, Williams, Paul, Baer, John, Mangeshkar, Milan, Scheffold, Christian, Hutson, Thomas E., Pal, Sumanta, and Motzer, Robert J.

Published
2018
Full Text
View/download PDF

44. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.

Author

Escudier, Bernard, Powles, Thomas, Motzer, Robert J., Olencki, Thomas, Arén Frontera, Osvaldo, Oudard, Stephane, Rolland, Frederic, Tomczak, Piotr, Castellano, Daniel, Appleman, Leonard J., Drabkin, Harry, Vaena, Daniel, Milwee, Steven, Youkstetter, Jillian, Lougheed, Julie C., Bracarda, Sergio, Choueiri, Toni K., and Arén Frontera, Osvaldo

Published
2018
Full Text
View/download PDF

45. Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm.

Author

Tandstad, Torgrim, Kollmannsberger, Christian K., Roth, Bruce J., Jeldres, Claudio, Gillessen, Silke, Fizazi, Karim, Daneshmand, Siamak, Lowrance, William T., Hanna, Nasser H., Cedermark, Gabriella Cohn, Feldman, Darren R., Powles, Thomas, Lewis, Mark A., Grimison, Peter Scott, Bank, Douglas, Porter, Christopher, Albers, Peter, De Santis, Maria, Srinivas, Sandy, and Bosl, George J.

Published
2017
Full Text
View/download PDF

50. TROPHY-U-01 cohort 6: Sacituzumab govitecan (SG), SG plus zimberelimab (ZIM), SG plus ZIM plus domvanalimab (DOM), or carboplatin (CARBO) + gemcitabine (GEM) in cisplatin-ineligible patients (pts) with treatment-naive metastatic urothelial cancer (mUC).

Author

Duran, Ignacio, Necchi, Andrea, Powles, Thomas, Loriot, Yohann, Ramamurthy, Chethan, Recio-Boiles, Alejandro, Sweis, Randy F., Bedke, Jens, Tonelli, Julia, Sierecki, Mitch, Grivas, Petros, and Barthelemy, Philippe

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results